Due to the lack of commercially available PDK4 selective inhibitors, pharmacological pan-PDK inhibitors, such as dichloroacetate (DCA), which target the ATP-binding pockets of all PDK isozymes, have been used to investigate metabolic diseases associated with mitochondrial dysfunction. This evidence concerns the gene PDK4 and metabolic disease.